Effects of Livin gene RNA interference on apoptosis of cervical cancer Hela cells and enhanced sensitivity to cisplatin

Abstract

The recombinant plasmids pGenesil-1-BIRC71 and pGenesil-1-BIRC72 were transfected into Hela cells and cisplatin was added with different concentrations in order to study the inhibitory effects of Livin gene, increase the apoptosis induced by cisplatin, and detect the expression of Bcl-2, Bax, caspase-3, and survivin genes. The pGenesil-1-BIRC71 and pGenesil-1-BIRC72 were transfected into Hela cells, and the expression levels of Livin, Bcl-2, Bax, caspase-3, and survivin genes were detected by using fluorescence quantitative real-time PCR. Then cisplatin at different concentrations (3.0, 6.0 and 9.9 µg/mL) was added into the transfected Hela cells, and 24, and 48 h later, the apoptosis rate was measured by flow cytometry. After transfection of pGenesil-1-BIRC71 and pGenesil-1-BIRC72 into Hela cells, the expression level of Livin gene was obviously reduced, and the apoptosis rate was significantly increased in transfection group as compared with control group (P<0.05). Cisplatin could increase the apoptosis rate in a dose- and time-dependent manner. After cisplatin was added, the expression levels of Bcl-2 mRNA were reduced, and those of Bax, caspase-3, and survivin mRNA were increased in transfection group as compared with those in control group (P<0.05). It was concluded that shRNA expression vector targeting Livin gene could inhibit the expression of Livin gene in Hela cells and enhance the apoptosis induced by cisplatin, which was related to the decreased expression of Bcl-2 and activation of Bax and caspase-3. Survivin might play an important role as an antagonist in the process of apoptosis induction.

Keywords

Livin / shRNA / pGenesil-1 / Hela cell / cisplatin

References

[1] AshhabY., AlianA., PolliackA., et al.. Two splicing variants of a new inhibitor of apoptosis gene with different biological properties and tissue distribution pattern. FEBS Lett, 2001, 495(1–2): 56-60

[2] JuD.W., TaoQ., ChengD.S., et al.. Adenovirus-mediated lymphotactin gene transfer improves therapeutic efficacy of cytosine deaminase suicide gene therapy in established murine colon carcinoma. Gene Ther, 2000, 7(4): 329-338

[3] YuL.L., WangZ.H.. Construction of Livin shRNA eukaryotic expression vectors. J Huazhong Univ Sci Technol Med Sci, 2007, 36(3): 489-491

[4] Varela-LedoE., Romero-YusteS., Ordóñez-BarbosaP., et al.. CMV DNA detection in plasma using real-time PCR based on the SYBR-Green I dye method. Enferm Infecc Microbiol Clin, 2006, 24(9): 541-545

[5] WangL., ZhangQ., LiuB., et al.. Challenge and promise: roles for Livin in progression and therapy of cancer. Mol Cancer Ther, 2008, 7(12): 3661-3369

[6] WilkinsonJ.C., CeperoE., BoiseL.H., et al.. Upstream regulatory role for XIAP in receptor-mediated apoptosis. Mol Cell Biol, 2004, 24(16): 7003-7014

[7] KempkensteffenC., HinzS., KrauseH., et al.. Expression of splicing variants of the inhibitor of apoptosis livin in testicular germ cell tumors. Tumour Biol, 2008, 29(2): 76-82

[8] GazzanigaP., GradiloneA., GiulianiL., et al.. Expression and prognostic significance of Livin, Survivin and other apoptosis-related genes in the progression of superficial bladder cancer. Ann Oncol, 2003, 14(1): 85-90

[9] LiuB., HanM., WenJ.K., et al.. Livin/ML-IAP as a new target for cancer treatment. Cancer Lett, 2007, 250(2): 168-176

[10] LiangC.Y., MaP., LiuX.L.. RNAi-mediated gene silencing of livin synergistic with epirubicin enhance apoptosis of human breast cancer cells. Zhonghua Yi Xue Za Zhi, 2008, 88(24): 1703-1706

[11] YuanD., LiuL., XuH., et al.. The effects on cell growth and chemosensitivity by livin RNAi in non-small cell lung cancer. Mol Cell Biochem, 2009, 320(1–2): 133-140

[12] WangH., TanS.S., WangX.Y., et al.. Effects of siRNA on expression of livin and dose- and time-response in human malignant melanoma LiBr cells. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi (Chinese), 2007, 23(8): 741-744

[13] KasofG.M., GomesB.C.. Livin, a novel inhibitor of apoptosis protein family member. J Biol Chem, 2001, 276(5): 3238-3246

[14] KasofG.M., ProsserJ.C., LiuD., et al.. The RIP-like kinase, RIP3, induces apoptosis and NF-kappaB nuclear translocation and localizes to mitochondria. FEBS Lett, 2000, 473(3): 285-291

[15] NachmiasB., AshhabY., BucholtzV., et al.. Caspase- mediated cleavage converts Livin from an antiapoptotic to a proapoptotic factor: implications for drug- resistant melanoma. Cancer Res, 2003, 63(19): 6340-6349

[16] StegeA., PriebschA., NiethC., et al.. Stable and complete overcoming of MDR1/ P-glycoprotein-mediated multidrug resistance in human gastric carcinoma cells by RNA interference. Cancer Gene Ther, 2004, 11(11): 699-706

[17] Crnkovic-MertensI., Hoppe-SeylerF., ButzK.. Induction of apoptosis in tumor cells by siRNA-mediated silencing of the livin/ML-IAP/KIAP gene. Oncogene, 2003, 22(51): 8330-8336

[18] ChangH., SchimmerA.D.. Livin/melanoma inhibitor of apoptosis protein as a potential therapeutic target for the treatment of malignancy. Mol Cancer Ther, 2007, 6(1): 24-30

[19] VucicD., StennickeH.R., PisabarroM.T., et al.. ML-IAP, a novel inhibitor of apoptosis that is preferentially expressed in human melanomas. Curr Biol, 2000, 10(21): 1359-1366

[20] KluckR.M., Bossy-WetzelE., GreenD.R., et al.. The release of cytochrome C from mitochondria: a primary site for Bcl-2 regulation of apoptosis. Science, 1997, 275(5303): 1132-1136

[21] ShinS., SungB.J., ChoY.S., et al.. An anti-apoptotic protein human survivin is a direct inhibitor of caspase-3 and -7. Biochemistry, 2001, 40(4): 1117-1123

[22] WangR., LinF., WangX., et al.. The therapeutic potential of survivin promoter-driven siRNA on suppressing tumor growth and enhancing radiosensitivity of human cervical carcinoma cells via downregulating hTERT gene expression. Cancer Biol Ther, 2007, 6(8): 1295-12301

[23] LuoK.Q., ChangD.C.. The gene-silencing effciency of siRNA is strongly dependent on the local structure of mRNA at the targeted region. Biochem Biophys Res Commun, 2004, 318(1): 303-310

[24] OverhoffM., AlkenM., FarR.K., et al.. Local RNA target structure influences siRNA efficacy: a systematic global analysis. J Mol Biol, 2005, 348(4): 871-881

[25] YangY.L., LiX.M.. The IAP family: endogenous caspase inhibitors with multiple biological activities. Cell Res, 2000, 10(3): 169-177